Novartis offered up $25 million in cash last November for the rights to Mesoblast’s potential cell therapy for Covid-19. But after a Phase III flunk, the Big Pharma’s now getting cold feet — and…
Breakthroughs in drug development have begun to unlock the potential of antibody-drug conjugates, therapies designed to better target proteins on tumor cells. Genentech’s Polivy has become an early…
Since the pandemic began in the spring of 2020, Tillman Gerngross has raised more than half a billion dollars for his startup Adagio and their promise to develop a so-called broadly neutralizing…
The drastic difference in efficacy for Merck’s Covid-19 pill between interim and final analyses — from a 50% relative reduction in hospitalizations and deaths at the interim to just 30% in the final…
John Carroll: Well, hello everybody. This is John Carroll. I’m the editor of Endpoints News, the editor and founder of Endpoints News. I’m here with Jay Bradner, the president of the Novartis…
During the Covid-19 pandemic, local pharmacies were not only key purveyors of prescriptions and hand sanitizer, but also important testing and vaccine delivery locations. Next up? Clinical trial…
Just a few weeks after offering a positive readout on its first early clinical-stage offering, the transatlantic biotech Immatics is back with news that the research crowd around Rupert Vessey at…
Rob Califf, the famous cardiologist from Duke University, is likely to return to the top of the FDA, this time under the Biden administration. At his confirmation hearing Tuesday, Democrats and…
In China, the character 安, pronounced An in English phonics, has a few different translations — yet they all come to the same general meaning: calm, safe, comfortable. And for precision oncology…
A new private study by South Africa’s largest insurer, Discovery Health, suggests that Pfizer and BioNTech’s Covid-19 vaccine is just 33% effective against infections by the Omicron variant. However,…
